What is AntiCancer?
AntiCancer, Inc. is a prominent biotechnology firm dedicated to pioneering innovative cancer research, with a particular focus on preclinical models. The company is recognized for its advanced orthotopic patient-derived xenograft (PDOX) models, offering a suite of products and services essential for drug discovery and evaluation. These include specialized fluorescent cell lines, diverse mouse models, and comprehensive contract research services. With a legacy spanning over 36 years and a robust portfolio of more than 1100 scientific publications, AntiCancer serves the pharmaceutical and research communities by providing cutting-edge solutions for cancer therapy development, notably in methioninase research, and has seen its methodologies validated through numerous clinical trials.
How much funding has AntiCancer raised?
AntiCancer has raised a total of $50K across 1 funding round:
Debt
$50K
Debt (2021): $50K with participation from PPP
What's next for AntiCancer?
The recent substantial expansion capital injection positions AntiCancer, Inc. for accelerated growth and further innovation in its specialized cancer research domain. This funding is expected to bolster its preclinical model development, enhance its contract research capabilities, and potentially expand its reach within the pharmaceutical and research sectors. As the company operates at a significant Series B/C stage, this investment signals confidence from backers in its long-term strategy and its capacity to advance novel cancer therapies through its established expertise and validated research models.
See full AntiCancer company page
